Dr. Manax, a renowned clinical oncologist with more than 20 years of experience in the pharmaceutical and biotech industries, brings a wealth of expertise in global drug and device development, nanomedicines, and the commercial launch of groundbreaking medical solutions.
Dr. Manax, a renowned clinical oncologist with more than 20 years of experience in the pharmaceutical and biotech industries, brings a wealth of expertise in global drug and device development, nanomedicines, and the commercial launch of groundbreaking medical solutions. Her innovative approach to clinical trial designs has been instrumental in the development and approval of major products, notably transforming the treatment landscape for pancreatic cancer.
Having held multiple leadership roles at influential companies like Abraxis Bioscience, Celgene (BMS), MedSurge PI, and Duo Oncology, Dr. Manax's extensive background is a testament to her profound impact on medical science and patient care. Her tenure as the inaugural Chief Medical Officer for the Pancreatic Cancer Action Network further highlights her commitment to advancing healthcare outcomes.
Dr. Manax expressed her enthusiasm for joining Eckuity Capital, citing the firm's access to exceptional investment opportunities and its strategic investment approach as key factors in her decision. "Eckuity Capital provides me the opportunity to bring together the things I love doing most," she stated, signaling a harmonious blend of her medical and investment expertise.
Youssef Sebban, Managing Partner of Eckuity Capital, emphasized the strategic value Dr. Manax adds to the firm, particularly in the realm of clinical trial design—a crucial element of therapeutic success and value creation in early-stage companies. "We are delighted to welcome Victoria to the team," Sebban remarked, underscoring the anticipated positive impact of her contributions on the firm's investments.
Eckuity Capital, with offices in New York, London, and Paris, continues to solidify its position as a leading investor in life science, healthcare, and technology. By marrying scientific, medical, and business acumen, the firm actively partners with entrepreneurs to foster innovation, accelerate success, and enhance the human condition through impactful healthcare solutions.
Jay Goldberg is a staff writer at TechEchelon covering technology, markets, and policy. He files the breaking news and deal coverage that move the publication's core desks.
More from Jay →Silicon Data has partnered with CME Group to develop the first futures contracts tied to AI computing power costs, giving companies a potential tool to hedge against GPU rental-rate volatility. The contracts are still awaiting CFTC approval.
Apple CEO Tim Cook told the Wall Street Journal that price increases on the company's products are "unavoidable" due to a worsening global memory shortage driven by AI chip demand, signaling the supply crunch has reached even the most insulated players in consumer hardware.
South Korea's Kospi surged 2.8% as Samsung Electronics and SK Hynix reached all-time highs, while U.S. chip stocks including Intel and Micron powered a broad market rebound following a volatile Federal Reserve policy meeting.
Written for readers who already know the basics — markets, AI, and the policy decisions that shape both.